KoYH, JoeSH, JungIK, KimSH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol2005;28:169-75.
2.
AfsharH, RoohafzaH, MousaviG. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol2009;23:157-62. DOI 10.1177/0269881108089816
3.
TiihonenJ, HalonenP, WahlbeckK. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry2005;66:1012-5.
4.
DeutschSI, SchwartzBL, RosseRB, MastropaoloJ, MarvelCL, DrapalskiAL. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol2003;26:199-206.
5.
NarulaPK, RehanHS, UnniKE, GuptaN.Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 2010. DOI 10.1016/j.schres.2010.02.001
